Hyperbaric oxygen therapy effectively alleviates D-galactose-induced-age-related cardiac dysfunction via attenuating mitochondrial dysfunction in pre-diabetic rats.

What Researchers Did

Researchers investigated whether hyperbaric oxygen therapy (HBOT) could alleviate D-galactose-induced cardiac dysfunction by improving mitochondrial function in pre-diabetic rats.

What They Found

The study involved 56 Wistar rats, divided into 7 groups, receiving either a normal or high-fat diet for 12 weeks, followed by D-galactose or vehicle injections for 8 weeks. HBOT, administered daily for 60 minutes at 2 atmospheres absolute, reduced metabolic impairments and mitochondrial dysfunction. This treatment also increased autophagy, leading to improved cardiac function in aged pre-diabetic rats.

Canadian Relevance

This study has no direct Canadian connection as it was not conducted in Canada, nor does it involve Canadian researchers or patients.

Study Limitations

A significant limitation of this study is that its findings are based on animal models (rats) and may not directly translate to human patients.